An investment research firm wanted to prove AI could revolutionize drug development. So they teamed up with Anthropic to see whether an unreleased version of Claude could make scorpion antivenom. It couldn't. It came up with some promising starting points, but nothing close to an actual drug, experts tell The Verge.
Citrini Research, the firm behind the experiment, admitted that "none of us could claim to know anything about AI as it related to biology." That didn't stop it from trying to make a drug from scratch - or publishing a blog post titled "We Wanted to Use Claude to Create a New Drug.
